ClinicalTrials.gg
Drug

Disitamab vedotin clinical trials

Also written RC48-ADC.

studies test it
117
open now
87
in phase 3
14
first study started
2015

How each study uses disitamab vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the disitamab vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Disitamab Vedotin
38
Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection
8
Disitamab Vedotin (RC48)
5
Disitamab Vedotin Injection
4
RC48, RC48-ADC
3

Development codes

RC48-ADC
51

In one entry with another drug

Given together, or one or the other

Disitamab Vedotin and Toripalimab
2
RC48 Combined With Tislelizumab
2
Disitamab Vedotin combined with Sintilimab
2
RC48-ADC and JS001
2

Studies by the year they started

115 studies that test it; most in 2023 (34); 2 more planned to start later

Studies that test disitamab vedotin, by start year
YearStudies
20151
20162
20171
20183
20192
20203
20215
202217
202334
202422
202513
202612

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
17
Phase 2
96
Phase 3
14
Phase 4
4
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 35 · Other 82

RemeGen Co., Ltd. (29) · Fudan University (7) · RenJi Hospital (7) · Qilu Hospital of Shandong University (5) · Sun Yat-sen University (5) · Seagen, a wholly owned subsidiary of Pfizer (4) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (4) · West China Hospital (4)

Often tested with

Tested in the same studies.

Tislelizumab (10) · Toripalimab (9) · Sintilimab (7) · Cadonilimab (5) · HMPL-013 (3) · Capecitabine (3) · Penpulimab (3) · Immune checkpoint inhibitors (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 21, 3 in phase 3

Studies that test disitamab vedotin, phase 3 first.

Studies

Open first, then newest update. How each study uses disitamab vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 117

See all 117 studies that test disitamab vedotin →

Given beside what is tested · 13 — disitamab vedotin is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with disitamab vedotin

Codes

What other systems call disitamab vedotin · ClinicalTrials.gg INT001915

  • MeSH (NLM) C000722994disitamab vedotinOne source ClinicalTrials.gov
  • UNII (FDA) RB3U3A1S27DISITAMAB VEDOTINOne source FDA
  • NCI Thesaurus C169918Disitamab VedotinOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.